

Supplementary references

- S1. Mcquarrie EP, Mackinnon B, Young B, *et al.* Centre variation in incidence, indication and diagnosis of adult native renal biopsy in Scotland. *Nephrol Dial Transpl.* 2009;24:1524-1528.
- S2. Hall YN, Fuentes EF, Chertow GM, Olson JL. Race/ethnicity and disease severity in IgA nephropathy. *BMC Nephrol.* 2004;5(1):10.
- S3. Schena FP. Immunogenetic aspects of primary IgA nephropathy. *Kidney Int.* 1995;48(6):1998-2013.
- S4. Schena FP, Cerullo G, Rossini M, *et al.* Increased risk of end-stage renal disease in familial IgA nephropathy. *J Am Soc Nephrol.* 2020;13(2):453-60.
- S5. Ripke S, Neale BM, Corvin A, *et al.* Biological insights from 108 schizophrenia-associated genetic loci. *Nature.* 2014;511(7510):421-427.
- S6. Damen JAAG, Hooft L, Schuit E, *et al.* Prediction models for cardiovascular disease risk in the general population: Systematic review. *BMJ.* 2016;353.
- S7. Barbour SJ, Coppo R, Zhang H, *et al.* Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. *JAMA Intern Med.* 2019;179(7).
- S8. Serino G, Pesce F, Sallustio F, *et al.* In a retrospective international study, circulating MIR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. *Kidney Int.* 2016;89(3):683-92.
- S9. Koulouridis E, Koulouridis I. Is the dietary protein restriction achievable in chronic kidney disease? The impact upon quality of life and the dialysis delay. *Hippokratia.* 2011;15(SUPPL. 1):3-7.
- S10. Konishi Y, Okada N, Okamura M, *et al.* Sodium Sensitivity of Blood Pressure Appearing Before Hypertension and Related to Histological Damage in Immunoglobulin A Nephropathy. *Hypertension.* 2001;38(1):81-85.
- S11. Kittiskulnam P, Kanjanabuch T, Tangmanjitjaroen K, *et al.* The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: A randomized controlled trial. *J Ren Nutr.* 2014;24(3):200-207.
- S12. Yamamoto R, Nagasawa Y, Shoji T, *et al.* Cigarette smoking and progression of IgA nephropathy. *Am J Kidney Dis.* 2010;56(2):313-324.
- S13. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. *Nat Rev Genet.* 2018;19(9):581-590.
- S14. Schena FP, Serino G, Sallustio F, *et al.* Omics studies for comprehensive understanding of immunoglobulin A nephropathy: State-of-the-art and future directions. *Nephrol Dial Transplant.* 2018;33(12).
- S15. Jeong KH, Kim JS, Lee YH, *et al.* Genome-wide association study identifies new susceptible loci of IgA nephropathy in Koreans. *BMC Med Genomics.* 2019;12(1). doi:10.1186/s12920-019-0568-6